<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232280</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1647-P202</org_study_id>
    <nct_id>NCT04232280</nct_id>
  </id_info>
  <brief_title>Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults</brief_title>
  <official_title>A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647
      cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years
      of age.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Observer-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of solicited local and systemic adverse reactions (ARs)</measure>
    <time_frame>7 days following each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of unsolicited adverse events (AEs)</measure>
    <time_frame>28 days following each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of medically-attended adverse events (MAAEs)</measure>
    <time_frame>6 months following the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>One year following the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in geometric mean titer (GMT) of serum neutralizing anti-CMV antibodies against epithelial cell infection and against fibroblast infection</measure>
    <time_frame>Up to Day 504</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥ 2-fold, 3-fold, and 4-fold increases in neutralizing antibodies over baseline against epithelial cell infection and against fibroblast infection</measure>
    <time_frame>Up to Day 504</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of anti-gB specific IgG and anti-Pentamer specific IgG as measured by enzyme-linked immunosorbent assay (ELISA), and associated GMR of post-baseline/baseline titers</measure>
    <time_frame>Day 1, 29, 56, 84, 168, 196, 336, and 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT, GMR, and proportion of participants with ≥ 2-fold, 3-fold, and 4-fold increases over baseline of serum nAb against epithelial cell infection and against fibroblast infection</measure>
    <time_frame>Day 1, 29, 56, 84 , 168, 196, 336, and 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT and GMR of antigen-specific IgG (ELISA) in the CMV-seropositive group</measure>
    <time_frame>Day 1, 29, 56, 84 , 168, 196, 336, and 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT and GMR of antigen-specific IgG (ELISA) in the CMV-seronegative group</measure>
    <time_frame>Day 1, 29, 56, 84 , 168, 196, 336, and 504</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>CMV-seronegative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMV-seropositive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1647</intervention_name>
    <description>Cytomegalovirus vaccine</description>
    <arm_group_label>CMV-seronegative</arm_group_label>
    <arm_group_label>CMV-seropositive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>CMV-seronegative</arm_group_label>
    <arm_group_label>CMV-seropositive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18-40 years of age

          -  Understands and agrees to comply with the trial procedures and provides written
             informed consent

          -  According to the assessment of the Investigator, is in good general health and is
             capable of complying with trial procedures

          -  Body mass index (BMI) 18-35 kg/m2

          -  Female subjects must either be of non-childbearing potential or use acceptable methods
             of contraception from at least 30 days prior to enrollment and through 3 months
             following last vaccination

          -  Male subjects must agree to practice adequate contraception for 30 days prior to the
             first vaccination and through 3 months following the last vaccination

        Exclusion Criteria:

          -  Acutely ill or febrile on the day of the first vaccination

          -  Prior receipt of any CMV vaccine

          -  Abnormal screening safety laboratory test results

          -  Diagnosis or condition that, in the judgment of Investigator, is clinically unstable
             or may affect participant safety, assessment of safety endpoints, assessment of immune
             response, or adherence to trial procedures

          -  Has received or plans to receive a vaccine ≤ 28 days prior to the first vaccination or
             plans to receive a non-study vaccine within 28 days prior to or after any study
             vaccination, except for any licensed influenza vaccine which can be administered &gt; 14
             days before or after any study vaccination

          -  Prior receipt of chronic systemic immunosuppressants or immune-modifying drugs

          -  Receipt of intravenous immunoglobulins or plasma products within 3 months prior to the
             day of the first study vaccination

          -  Previous receipt of medications in lipid nanoparticle (LNP) formulation

          -  Has donated ≥ 450 mL of blood products within 28 days of the Screening visit

          -  Participated in an interventional clinical trial within 28 days prior to the day of
             enrollment

          -  Is an immediate family member or household member of trial personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic-South Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderna</keyword>
  <keyword>mRNA-1647</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>Cytomegalovirus Vaccine</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Cytomegalovirus Congenital</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Infection Viral</keyword>
  <keyword>DNA Virus Infections</keyword>
  <keyword>Messenger RNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

